OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions	251
Necroptosis and tumor progression	217
Gut Microbiota in Cancer Immune Response and Immunotherapy	165
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors	154
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy	115
Better together: circulating tumor cell clustering in metastatic cancer	112
Challenges in glioblastoma research: focus on the tumor microenvironment	109
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy	105
Inflammation: the incubator of the tumor microenvironment	98
Extracellular Vesicles in Cancer Detection: Hopes and Hypes	96
Precision therapy for RET-altered cancers with RET inhibitors	94
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance	94
Targeting CAFs to overcome anticancer therapeutic resistance	90
Targeting ferroptosis in pancreatic cancer: a double-edged sword	88
Revisiting the HIF switch in the tumor and its immune microenvironment	88
FTO in cancer: functions, molecular mechanisms, and therapeutic implications	86
Tweak to Treat: Reprograming Bacteria for Cancer Treatment	83
The emerging field of oncolytic virus-based cancer immunotherapy	81
TRAIL of Hope Meeting Resistance in Cancer	80
Therapeutic targeting of regulatory T cells in cancer	78
Antibody–drug conjugates: in search of partners of choice	78
Drug independence and the curability of cancer by combination chemotherapy	75
Targeting SUMO Signaling to Wrestle Cancer	73
T follicular helper cells in cancer	72
C1q+ macrophages: passengers or drivers of cancer progression	72

Utilizing chemokines in cancer immunotherapy	71
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	70
Radiotherapy and immunotherapy: open questions and future strategies	69
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm	68
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma	67
Pharmacological Targeting of IRE1 in Cancer	66
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids	64
Targeting the Mevalonate Pathway in Cancer	64
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer	64
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	63
Coagulome and the tumor microenvironment: an actionable interplay	58
Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis	56
The spectrum of sex differences in cancer	56
Cell death, therapeutics, and the immune response in cancer	56
How cancer cells make and respond to interferon-I	55
Cancer Plasticity: The Role of mRNA Translation	55
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy	54
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity	54
Evolution of metastasis: new tools and insights	54
Roles and Regulations of TET Enzymes in Solid Tumors	52
Targeting the replication stress response through synthetic lethal strategies in cancer medicine	49
Tumor Innervation: Cancer Has Some Nerve	49
Nanomedicine-based strategies to target and modulate the tumor microenvironment	49
Single cell cancer epigenetics	48
Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer	48
Emerging Players in Prostate Cancer–Bone Niche Communication	48
Liver Inflammation and Hepatobiliary Cancers	48
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology	46
Cancer of Unknown Primary in the Molecular Era	45
Hypertranscription and replication stress in cancer	44
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	43
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer	42
Technical and biological constraints on ctDNA-based genotyping	42
T cell exhaustion in malignant gliomas	42
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides	40
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	40
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy	40
Therapeutic Repurposing of Biguanides in Cancer	39
Why Great Mitotic Inhibitors Make Poor Cancer Drugs	39
Immune mechanisms of toxicity from checkpoint inhibitors	38
HLA-G/LILRBs: A Cancer Immunotherapy Challenge	38
Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks	37
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy	37
Tissue architecture in tumor initiation and progression	36
Mitochondrial DNA is a major source of driver mutations in cancer	36
Microfluidics meets 3D cancer cell migration	36
Chromosomal instability and aneuploidy as causes of cancer drug resistance	36
Tumour microenvironment 3D-modelling: simplicity to complexity and back again	35
Neuronal and tumourigenic boundaries of glioblastoma plasticity	35
Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment	35

Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer	35
Bispecific Antibodies for Triple Negative Breast Cancer	34
How Comorbidities Shape Cancer Biology and Survival	34
Cancer cell adaptability: turning ribonucleoprotein granules into targets	34
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	33
Cellular and molecular mechanisms of plasticity in cancer	33
Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research	32
The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity	32
Age-associated differences in the cancer molecular landscape	31
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	31
Preclinical to clinical utility of ROCK inhibitors in cancer	31
Tackling PARP inhibitor resistance	30
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	30
Immune response and inflammation in cancer health disparities	29
Emerging metabolomic tools to study cancer metastasis	29
Modulating Treg stability to improve cancer immunotherapy	29
Exploiting cancer’s drinking problem: regulation and therapeutic potential of macropinocytosis	29
Role of financial toxicity in perpetuating health disparities	29
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma	29
DNA Damage Repair Deficiency in Prostate Cancer	29
Human-Derived Model Systems in Gynecological Cancer Research	28
Mice Are Not Humans: The Case of p53	28
Emerging mechanisms of telomerase reactivation in cancer	28
From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts	28
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	27
Group Behavior and Emergence of Cancer Drug Resistance	27
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy	27
T cell-mediated additive cytotoxicity – death by multiple bullets	27
Immune organoids: from tumor modeling to precision oncology	26
Ecology and evolution of dormant metastasis	25
The Anticancer Potential of T Cell Receptor-Engineered T Cells	25
Synthetic Lethal Interactions of RECQ Helicases	25
Tumor Excision as a Metastatic Russian Roulette: Perioperative Interventions to Improve Long-Term Survival of Cancer Patients	24
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	24
Beyond matrix stiffness: targeting force-induced cancer drug resistance	24
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	24
Aneuploidy in Cancer: Lessons from Acute Lymphoblastic Leukemia	24
GSDME: A Potential Ally in Cancer Detection and Treatment	24
Immunity beyond cancer cells: perspective from tumor tissue	24
Engineering stem cells for cancer immunotherapy	24
Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms	24
Pannexin biology and emerging linkages to cancer	23
Epigenetic basis and targeting of cancer metastasis	23
New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?	23
Tumor mutational burden and immunotherapy in gliomas	23
Leveraging Single-Cell Approaches in Cancer Precision Medicine	22
Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities	22
The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer	22
Radiotherapy-induced metabolic hallmarks in the tumor microenvironment	22
Computing the Role of Alternative Splicing in Cancer	22
CHEK2 variants: linking functional impact to cancer risk	22
Next batter up! Targeting cancers with KRAS-G12D mutations	22
Targeting synthetic lethal paralogs in cancer	22
Mechanisms of PDAC subtype heterogeneity and therapy response	22
Senescent stromal cells: roles in the tumor microenvironment	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Fluorescence Sheds Light on DNA Damage, DNA Repair, and Mutations	22
Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas	21
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy	21
Capicua in Human Cancer	20
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	19
Fasting and fasting mimicking diets in cancer prevention and therapy	19
Interleukin-10 in cancer immunotherapy: from bench to bedside	19
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance	19
Implications of Tumor–Immune Coevolution on Cancer Evasion and Optimized Immunotherapy	18
The unequal burden of time toxicity	18
Collagen architecture and signaling orchestrate cancer development	18
Tumor immunology CRISPR screening: present, past, and future	18
Exploiting T cell signaling to optimize engineered T cell therapies	18
Intestinal stem cell dynamics in homeostasis and cancer	18
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents	18